Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lophius Biosciences Joins NEU² Program

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Company receives substantial grant funding for the diagnosis and monitoring of multiple sclerosis.

Bionamics GmbH and Lophius Biosciences GmbH have announced that Lophius Biosciences has joined the NEU² program with a project addressing the development of T-Track® MS as a novel blood-based diagnostic test supporting the initial diagnosis of multiple sclerosis (MS) and enabling the monitoring of MS disease progression.

This new project is to last for about two years with a funding of > 350.000 EUR proportionally supplied by The Federal Ministry of Education and Research (BMBF) under the BioPharma initiative.

Lophius Biosciences is a leading developer of innovative T cell based diagnostic test systems. One of the company’s platform technologies, the “Reverse T Cell Technology (RTT)”, represents a novel strategy for the diagnosis of T cell-mediated diseases.

In contrast to available methods, RTT exploits the maturation processes induced in antigen presenting cells (APC) via a specific interaction with activated T helper (Th) cells thus representing an indirect measure for activated Th cells.

Due to the high specificity of RTT for activated Th cells, the intended use of the RTT assay is the reliable detection of disease-specific activated Th cells as a novel biomarker for the diagnosis and monitoring of ongoing autoimmune diseases such as MS.

The T-Track® MS test is aimed to fulfill unmet clinical needs offering a blood-based rapid and reliable differential diagnosis of MS complementary to the today’s clinical and MRT based diagnosis.

Initial data from a collaboration between Lophius Biosciences and the Clinic and Policlinic for Neurology, University of Regensburg, and the Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology Hamburg, demonstrated preliminary clinical proof of principle for this MS test.

Dr. Michael Lutz and Prof. Dr. Ralf Wagner, Managing Directors of Lophius Biosciences commented: “We are very pleased to join the NEU² consortium. Both the opportunity to interact with leading experts in the MS field as well as the substantial funding will accelerate the development of our highly innovative T cell based diagnostic T-Track® MS test kit and help Lophius to initiate a broader clinical discovery and development program.”

Dr. Timm Jessen, CEO of Bionamics GmbH and founder of NEU², about the further expansion of the NEU² consortium: “With Lophius Biosciences we could attract an attractive new partner for the consortium. Its expertise in the diagnostic area will complement our expertises within NEU², also to the benefit of our current consortium members.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations
Dr. Phelps has longstanding experience in business development and licensing.
Wednesday, December 04, 2013
Lophius Biosciences Closes Financing Round and Expands Management Board
Lophius Biosciences announces the closing of a further financing round with Prof. Dr Ralf Wagner been appointed as Managing Director.
Tuesday, January 22, 2013
Lophius Biosciences Achieves First Clinical Proof of Principle for T-Track® TB
Clinical proof of principle for detection of active tuberculosis and receives research funding.
Thursday, November 08, 2012
Lophius Biosciences Concludes TB Detection Trials
Company achieves first clinical Proof of Principle for T-Track® TB for detection of active tuberculosis and receives research funding.
Thursday, November 08, 2012
Lophius Biosciences Completes Necessary Regulatory Milestones with EN ISO 13485 Certification
Company has received CE-marking for its T-Track® CMV and T-Track® EBV tests.
Friday, June 01, 2012
Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR
Financial investors such as S-Refit, High-Tech Gründerfonds and Bayernkapital participated in this financing round.
Tuesday, July 19, 2011
Lophius Biosciences Expands its Management Team and Prepares for Market Entry at the Beginning of 2012
The team is completed by Dr. Zanker from MedicalDevice+, an experienced expert in the field of regulatory affairs for diagnostic products.
Tuesday, July 12, 2011
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Supplement May Switch off Cravings for High-Calorie Foods
Propionate is made by bacteria in the gut after they digest fiber, with researchers finding higher levels of the substance can curb cravings for junk food.
Implementation Science Approaches to Reduce Mother-to-Child HIV Transmission
The NIH study will investigate best practices to ease major disease burden in Sub-Saharan Africa.
Tough New Hydrogel Hybrid Doesn’t Dry Out
Water-based material could be used to make artificial skin, longer-lasting contact lenses.
New CAR T Cell Therapy Using Double Target Aimed at Solid Tumors
Researchers at Penn University have described how antibody, carbohydrate combination could apply to range of cancer types.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
Link Between Canned Food, BPA Exposure Revealed
New Stanford research resolves the debate on the link between canned food and exposure to the hormone-disrupting chemical known as Bisphenol A, or BPA.
Portable Test Rapidly Detects Zika
To better diagnose and track the disease, scientists are now reporting a new $2 test that in the lab can accurately detect low levels of the virus in saliva.
Erasing Unpleasant Memories with a Genetic Switch
Researchers from KU Leuven and the Leibniz Institute for Neurobiology have managed to erase unpleasant memories in mice using a 'genetic switch'.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!